Document Detail


Serum paraoxonase 1 activity and oxidative markers of LDL in patients with cardiac syndrome X.
MedLine Citation:
PMID:  17608098     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Myocardial ischaemia in cardiac syndrome X (CSX) is believed to be due to microvascular dysfunction. Increased oxidative stress is one of the suspected mechanisms of microvascular dysfunction. The aim of this study was to evaluate the oxidative status in patients with CSX, by determining serum paraoxonase-1 (PON 1) activity in addition to LDL-oxidation markers. METHODS AND RESULTS: This cross-sectional study consisted of patients with CSX (group I, n = 30), patients with coronary artery disease (group II, n = 31), and healthy controls (group III, n = 32). Lipid parameters, PON-1 activity, and LDL oxidation markers (conjugated-diene and thiobarbituric acid-reactive substance-TBARS) were measured. Endothelium-dependent vasodilatation was determined by brachial artery ultrasonography. There were no significant differences in serum LDL, apolipoprotein-B, baseline LDL-diene, and LDL-TBARS levels between groups. There were no differences in both apolipoprotein-A1 and HDL levels between group I and group III. Apolipoprotein-A1 and HDL levels were significantly lower in group II than group I patients (P < 0.001). PON-1 activity was lowest in group II patients. Average PON-1 activity in group I was in between of group II and group Ill. The percent change of LDL-diene levels after stimulation was significantly higher in group II than in groups I and III (P = 0.005 and P = 0.02, respectively). The percent change of LDL-TBARS levels was lowest in group I (P = 0.03). There was a moderate correlation between endothelium-dependent vasodilatation and PON-1 activity in group I (r = 0.43, P = 0.04). CONCLUSIONS: Enhanced oxidative stress might be one of the causes of impaired endothelial functions resulting in myocardial ischaemia and chest pain in patients with CSX. The relatively preserved HDL and apolipoprotein-A1 levels in patients with CSX might be a protective mechanism against progression of coronary microvascular dysfunction to atherosclerotic coronary artery disease.
Authors:
Meral Kayikcioglu; Serkan Saygi; Elif Azarsiz; Levent H Can; Hakan Kultursay; Eser Yildirim Sözmen
Related Documents :
15857308 - Ezetimibe and other azetidinone cholesterol absorption inhibitors.
9211018 - Retardation of coronary atherosclerosis: the bezafibrate coronary atherosclerosis inter...
15770338 - New trends in lipid management: eight cases to consider.
10769278 - Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by ...
23800548 - Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodys...
14980708 - Immunolocalization of lipid peroxidation/advanced glycation end products in amyloid a a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta cardiologica     Volume:  62     ISSN:  0001-5385     ISO Abbreviation:  Acta Cardiol     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-07-04     Completed Date:  2007-07-31     Revised Date:  2009-06-11    
Medline Journal Info:
Nlm Unique ID:  0370570     Medline TA:  Acta Cardiol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  245-9     Citation Subset:  IM    
Affiliation:
Ege University School of Medicine, Departments of Cardiology, Izmir, Turkey. meral.kayikcioglu@ege.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Analysis of Variance
Apolipoproteins / blood
Aryldialkylphosphatase / blood*
Biological Markers / blood*
Brachial Artery / ultrasonography
Cross-Sectional Studies
Female
Humans
Lipoproteins, LDL / blood
Male
Microvascular Angina / blood*,  enzymology
Middle Aged
Oxidative Stress
Predictive Value of Tests
Thiobarbituric Acid Reactive Substances / metabolism
Turkey
Vasodilation
Chemical
Reg. No./Substance:
0/Apolipoproteins; 0/Biological Markers; 0/Lipoproteins, LDL; 0/Thiobarbituric Acid Reactive Substances; EC 3.1.8.1/Aryldialkylphosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of plasma adiponectin levels in young men with coronary artery disease.
Next Document:  Differences in risk factors for acute coronary syndromes between men and women.